These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3119696)

  • 21. Hyperprolactinemia in polycystic ovary syndrome.
    Luciano AA; Chapler FK; Sherman BM
    Fertil Steril; 1984 May; 41(5):719-25. PubMed ID: 6425087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
    Tresguerres JA; Esquifino AI
    Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relation between hyperprolactinemia and polycystic ovary syndrome].
    Hámori M; Szendei G; Kovács I; Somos P
    Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The inhibitory effect of dopamine agonists on LH release in women.
    Lachelin GC; Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1977 Apr; 44(4):728-32. PubMed ID: 576612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic control of gonadotrophin secretion in normal women and in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Clin Endocrinol (Oxf); 1984 Jan; 20(1):53-63. PubMed ID: 6420095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine.
    Sauder SE; Frager M; Case GD; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1984 Nov; 59(5):941-8. PubMed ID: 6434588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome.
    Ferriani RA; Silva de Sá MF; Moura MD; Moreira AC; Gomes UA
    Gynecol Endocrinol; 1989 Dec; 3(4):317-27. PubMed ID: 2516707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine response in normoprolactinemic patients with polycystic ovary disease: a preliminary report.
    Seibel MM; Oskowitz S; Kamrava M; Taymor ML
    Obstet Gynecol; 1984 Aug; 64(2):213-9. PubMed ID: 6234484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromocriptine for infertile males with mild hyperprolactinemia: hormonal and spermatogenic effects.
    Nishimura K; Matsumiya K; Tsuboniwa N; Yamanaka M; Koga M; Miura H; Tsujimura A; Uchida K; Kondoh N; Kitamura M; Okuyama A
    Arch Androl; 1999; 43(3):207-13. PubMed ID: 10624504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
    Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
    Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of bromocriptine on FSH and LH secretion in women with euprolactinemic anovulation (author's transl)].
    Mori H; Aisaka K; Kigawa T; Minakuchi H; Sakamoto S
    Nihon Sanka Fujinka Gakkai Zasshi; 1981 Oct; 33(10):1741-8. PubMed ID: 6796631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bromocriptine in polycystic ovarian disease: a controlled clinical trial.
    el Tabbakh GH; Loutfi IA; Azab I; Rahman HA; Southren AL; Aleem FA
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):301-6. PubMed ID: 3279350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
    Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
    Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of bromocriptine and dopamine on pituitary hormone secretion in women].
    Masaoka K; Hosoya N; Mori T; Watanabe H; Ohkura T; Kumasaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1982 Dec; 34(12):2155-62. PubMed ID: 6818310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antigonadotropic actions of prolactin. Study of 10 cases of women with hyperprolactinemia].
    Schaison G; Mowszowicz I; Cesselin E; Lagoguey M
    Nouv Presse Med; 1977 Feb; 6(6):425-8. PubMed ID: 320558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Failure of bromocriptine to suppress prolactin in majeptil-induced hyperprolactinemia.
    Yarkoni S; Spitz IM; Ben-David M; Polishuk WZ
    Acta Eur Fertil; 1978 Dec; 9(4):185-8. PubMed ID: 573042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic mechanisms and luteinizing hormone secretion. I. Acute administration of the dopamine agonist bromocriptine does not inhibit luteinizing hormone release in hyperprolactinemic women.
    Evans WS; Rogol AD; MacLeod RM; Thorner MO
    J Clin Endocrinol Metab; 1980 Jan; 50(1):103-7. PubMed ID: 7188612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The ovulation-inducing effect of CB-154 on normoprolactinemic anovulatory subjects (author's transl)].
    Tamura T; Minakami H
    Nihon Naibunpi Gakkai Zasshi; 1982 Jan; 58(1):49-62. PubMed ID: 6802683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.